Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.84 |
| ▸ | PTGDR | Q13258 | 11/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGFR | P43088 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900406 | 1.00 | PTGER4 (0.84) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL12900354 | 0.93 | PTGER4 (0.85) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL12900389 | 0.92 | PTGER4 (0.80) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL12000743 | 0.92 | PTGER4 (1.00) | PTGER4PTGDRPTGER2 | |
| SCHEMBL1748992 | 0.92 | PTGER4 (1.00) | PTGER4PTGDRPTGER2 | |
| SCHEMBL12585444 | 0.92 | PTGER4 (0.71) | PTGER4PTGDRPTGER2 | |
| SCHEMBL988305 | 0.91 | PTGER4 (0.78) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL12585190 | 0.91 | PTGER4 (0.78) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL12900385 | 0.91 | PTGER4 (0.81) | PTGER4PTGDRTBXA2RPTGER1PTGFR | |
| SCHEMBL27855423 | 0.91 | PTGER4 (0.78) | PTGER4PTGDRTBXA2RPTGER1PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 13/4885TBXA2R 64/4885 |
| US-20110028463-A1 | AMIDE COMPOUNDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR 10/4885TBXA2R 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.